JPH11512708A - 変形性関節炎を治療するためのプロテインチロシンキナーゼインヒビター - Google Patents

変形性関節炎を治療するためのプロテインチロシンキナーゼインヒビター

Info

Publication number
JPH11512708A
JPH11512708A JP9513463A JP51346397A JPH11512708A JP H11512708 A JPH11512708 A JP H11512708A JP 9513463 A JP9513463 A JP 9513463A JP 51346397 A JP51346397 A JP 51346397A JP H11512708 A JPH11512708 A JP H11512708A
Authority
JP
Japan
Prior art keywords
tyrosine kinase
protein tyrosine
inhibitor
kinase inhibitor
tyrphostin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9513463A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11512708A5 (2
Inventor
アール． シャーペ，トーマス
ダブリュ． ヴァシオス，ジョージ
キャンプベル，アール．ネルソン
Original Assignee
オステオアルスリィティス サイエンシズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オステオアルスリィティス サイエンシズ，インコーポレイテッド filed Critical オステオアルスリィティス サイエンシズ，インコーポレイテッド
Publication of JPH11512708A publication Critical patent/JPH11512708A/ja
Publication of JPH11512708A5 publication Critical patent/JPH11512708A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP9513463A 1995-09-11 1996-09-11 変形性関節炎を治療するためのプロテインチロシンキナーゼインヒビター Pending JPH11512708A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52629095A 1995-09-11 1995-09-11
US08/526,290 1995-09-11
PCT/US1996/014491 WO1997011692A2 (en) 1995-09-11 1996-09-11 Protein tyrosine kinase inhibitors for treating osteoarthritis

Publications (2)

Publication Number Publication Date
JPH11512708A true JPH11512708A (ja) 1999-11-02
JPH11512708A5 JPH11512708A5 (2) 2004-09-30

Family

ID=24096728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9513463A Pending JPH11512708A (ja) 1995-09-11 1996-09-11 変形性関節炎を治療するためのプロテインチロシンキナーゼインヒビター

Country Status (8)

Country Link
US (2) US6552066B1 (2)
EP (1) EP0850055B1 (2)
JP (1) JPH11512708A (2)
AT (1) ATE298566T1 (2)
AU (1) AU709191B2 (2)
CA (1) CA2231509C (2)
DE (1) DE69634900T2 (2)
WO (1) WO1997011692A2 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500376A (ja) * 2000-01-24 2004-01-08 ジェンザイム・コーポレーション Ｊａｋ／ｓｔａｔ経路阻害剤およびその使用

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011692A2 (en) * 1995-09-11 1997-04-03 Osteoarthritis Sciences, Inc. Protein tyrosine kinase inhibitors for treating osteoarthritis
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
DE19845372A1 (de) * 1998-10-02 2000-04-20 Gruenenthal Gmbh Verwendung von Katecholderivaten als Proteinaseninhibitoren
CN1136217C (zh) 1998-12-17 2004-01-28 霍夫曼-拉罗奇有限公司 作为jnk蛋白质激酶抑制剂的4-芳基羟吲哚
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
BR9916327A (pt) 1998-12-17 2001-09-18 Hoffmann La Roche Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
WO2000035921A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
US7070936B1 (en) 1999-01-13 2006-07-04 The Research Foundation Of State University Of New York Method for designing protein kinase inhibitors
ATE494388T1 (de) 1999-01-13 2011-01-15 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase- inhibitoren
EP1200127B1 (en) * 1999-07-21 2008-06-25 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
EP1875900A3 (en) * 2000-01-24 2010-07-21 Genzyme Corporation JAK/STAT pathway inhibitors and the use thereof for the treatment of osteoarthritis
CA2404919A1 (en) * 2000-04-06 2002-10-01 Kyowa Hakko Kogyo Co. Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
US7067550B2 (en) * 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
WO2002035987A2 (en) * 2000-11-03 2002-05-10 Massachusetts Institute Of Technology METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
CA2464214C (en) * 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
US7005445B2 (en) * 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
DE60313754T2 (de) * 2002-03-06 2008-01-24 The Medical Research and Education Trust, San Diego Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
WO2005003765A1 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab Isothermal titration calorimetry assays
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US20090226552A1 (en) * 2004-07-22 2009-09-10 Colorado State University Research Foundation Agents and methods for diagnosing osteoarthritis
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US7947676B2 (en) 2004-12-14 2011-05-24 Astrazeneca Ab Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
DE102005005274A1 (de) * 2005-02-04 2006-08-10 Peter Heger Verwendung von Hydroxystilben-haltigen Wirkstoffen zur Prävention und Behandlung chronisch-entzündlicher Erkrankungen
US7820683B2 (en) 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
ES2369739T3 (es) * 2006-03-20 2011-12-05 Seikagaku Corporation Agente terapéutico para la artritis reumatoide.
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2009026705A1 (en) * 2007-08-24 2009-03-05 The University Of Western Ontario Method of diagnosing and treating osteoarthritis
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
CN101396369B (zh) * 2008-08-07 2010-12-01 杜宁 槐角苷的制药应用
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0446120A (ja) 1990-06-11 1992-02-17 Kyowa Hakko Kogyo Co Ltd 血管新生抑制剤
ATE243253T1 (de) * 1990-07-06 2003-07-15 Rhone Poulenc Rorer Internat H Rezeptoren der wachstumsfaktoren aus fibroblasten
US5262565A (en) * 1990-11-16 1993-11-16 Eisai Co., Ltd. Naphthalene derivatives
EP0580609A1 (en) 1991-03-22 1994-02-02 Xenova Limited Pharmaceutical xanthone derivatives
DE69116576T2 (de) 1991-09-05 1996-10-10 Pharno Wedropharm Gmbh Aromatische sulfonamidderivate, ihre verwendung als enzyminhibitoren und diese verbindungen enthaltende pharmazeutische zusammensetzungen
GB2262524A (en) 1991-12-18 1993-06-23 Sandoz Ltd Pharmaceutically active 2-hydroxy-benzylamines
SK280617B6 (sk) 1992-01-16 2000-05-16 Hoechst Aktiengesellschaft Arylcykloalkylové deriváty, spôsob ich prípravy, f
WO1993016703A1 (en) 1992-02-24 1993-09-02 Smithkline Beecham Corporation Protein kinase c inhibitor
GB2280439B (en) 1992-03-11 1995-11-22 Xenova Ltd CD4 binding agents and inhibitors of collagenase and protein kinase C
JPH0725761A (ja) * 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd 軟骨保護剤
WO1995002420A2 (en) * 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
WO1995005824A1 (en) 1993-08-24 1995-03-02 Smithkline Beecham Corporation Aaptamines and method of use thereof
WO1995007935A1 (en) 1993-09-14 1995-03-23 Merck & Co., Inc. cDNA ENCODING A NOVEL HUMAN PROTEIN TYROSINE PHOSPHATASE
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
US5591740A (en) 1995-06-07 1997-01-07 Osteoarthritis Sciences, Incorporated Use of debromohymenialdisine for treating osteoarthritis
WO1997011692A2 (en) * 1995-09-11 1997-04-03 Osteoarthritis Sciences, Inc. Protein tyrosine kinase inhibitors for treating osteoarthritis
FR2753969B1 (fr) * 1996-09-27 1998-10-30 Adir Nouveaux derives de flavones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500376A (ja) * 2000-01-24 2004-01-08 ジェンザイム・コーポレーション Ｊａｋ／ｓｔａｔ経路阻害剤およびその使用
JP2012041354A (ja) * 2000-01-24 2012-03-01 Genzyme Corp Ｊａｋ／ｓｔａｔ経路阻害剤およびその使用

Also Published As

Publication number Publication date
US6552066B1 (en) 2003-04-22
CA2231509C (en) 2008-07-08
DE69634900D1 (de) 2005-08-04
EP0850055A2 (en) 1998-07-01
AU709191B2 (en) 1999-08-26
WO1997011692A3 (en) 1997-07-03
AU7107496A (en) 1997-04-17
WO1997011692A2 (en) 1997-04-03
DE69634900T2 (de) 2006-05-18
EP0850055B1 (en) 2005-06-29
CA2231509A1 (en) 1997-04-03
US20030060515A1 (en) 2003-03-27
ATE298566T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
EP0850055B1 (en) Protein tyrosine kinase inhibitors for treating osteoarthritis
Kim et al. The catabolic pathway mediated by Toll‐like receptors in human osteoarthritic chondrocytes
US6462019B1 (en) Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) Inhibitors of proteasomal activity for stimulating bone growth
Johansen et al. Regulation of YKL‐40 production by human articular chondrocytes
EP1477180A1 (en) Inhibitors of proteasomal activity for stimulating bone and hair growth
US6838436B1 (en) Inhibitors of proteasomal activity for stimulating bone growth
EP0831834B1 (en) Debromohymenialdisine and related compounds for treating osteoarthritis
Thompson et al. Inhibition of the adherence of cholera toxin and the heat-labile enterotoxin of Escherichia coli to cell-surface GM1 by oligosaccharide-derivatized dendrimers
KR102199273B1 (ko) 뼈 및 연부에 발생하는 거대 세포성 종양 또는 연골 육종의 예방 및 치료제
JP6243996B2 (ja) Ｂｃａｔ１阻害剤を使用する治療方法
Sah et al. Novel isonahocol E3 exhibits anti-inflammatory and anti-angiogenic effects in endothelin-1-stimulated human keratinocytes
KR20250051580A (ko) 피부 손상 오가노이드 모델 및 이를 이용한 약물 스크리닝 방법
US20120316111A1 (en) BMP-2 Upregulating Compounds For Healing Bone Tissue And Screening Methods For Selecting Such Compounds
EP2624816A2 (en) Stimulation of neuroregeneration by flavonoid glycosides
Hirasawa et al. Pharmacological analysis of the inflammatory exudate-induced histamine production in bone marrow cells
AU2005246961B2 (en) Inhibitors of proteasomal activity for stimulating bone and hair growth
HK1035870B (en) Inhibitors of proteasomal activity for stimulating hair growth
KR20180121046A (ko) Chip를 유효성분으로 포함하는 oct4의 발현을 억제하거나 유비퀴틴화를 촉진하기 위한 생물학적 조성물
HK1097456A (en) Inhibitors of proteasomal activity for stimulating bone and hair growth

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071120